The Effect of Lactoferrin on Pain Management Following Cesarean Section

Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexFemale
Age18-70
SponsorAin Shams University

About this trial

This study evaluates whether lactoferrin, a naturally occurring protein with anti-inflammatory and antioxidant properties, can improve pain control after cesarean section. Effective management of postoperative pain is essential to support maternal recovery, mobility, and the ability to care for the newborn, while minimizing reliance on opioid medications and their associated side effects.

In this randomized, double-blind, placebo-controlled trial, women undergoing elective cesarean section will receive either oral lactoferrin or a matching placebo in addition to standard postoperative analgesia. Lactoferrin will be administered starting before surgery and continued for 48 hours after delivery.

The study will assess whether lactoferrin reduces postoperative pain intensity and opioid consumption, and improves recovery outcomes such as time to mobilization, patient satisfaction, and incidence of common postoperative symptoms. Safety and tolerability will also be evaluated.

Eligibility criteria

Qualifiers

Referred to elective (non-emergency) cesarean section

Undergoing spinal anesthesia) with American Society of Anesthesiologists (ASA) classification I and II

Term gestational age

Disqualifiers

History of seizures

Pre-eclampsia or eclampsia

Hypertension

Use of narcotic painkillers for 24 h before the intervention

Trial design

Treatments tested in this trial

  • Lactoferrin
  • Placebo

Treatment groups

90 Participants
are divided into 2 treatment groups

Sponsors and collaborators